BBS-Bioactive Bone Substitutes Oyj Past Earnings Performance
Past criteria checks 0/6
BBS-Bioactive Bone Substitutes Oyj's earnings have been declining at an average annual rate of -15.1%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-15.1%
Earnings growth rate
-2.9%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | n/a |
| Return on equity | -70.5% |
| Net Margin | n/a |
| Next Earnings Update | 22 Feb 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BBS-Bioactive Bone Substitutes Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -3 | 1 | 0 |
| 31 Dec 22 | 0 | -3 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -3 | 1 | 0 |
| 30 Sep 21 | 0 | -3 | 1 | 0 |
| 30 Jun 21 | 0 | -3 | 1 | 0 |
| 31 Mar 21 | 0 | -3 | 1 | 0 |
| 31 Dec 20 | 0 | -3 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 0 |
| 30 Jun 20 | 0 | -2 | 1 | 0 |
| 31 Mar 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
| 30 Sep 19 | 0 | -2 | 1 | 0 |
| 30 Jun 19 | 0 | -2 | 1 | 0 |
| 31 Mar 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | 0 | 1 | 0 |
| 30 Sep 18 | 0 | -1 | 1 | 0 |
| 30 Jun 18 | 0 | -3 | 1 | 0 |
| 31 Mar 18 | 0 | -4 | 1 | 0 |
| 31 Dec 17 | 0 | -4 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -1 | 0 | 0 |
Quality Earnings: BONEHU0223 is currently unprofitable.
Growing Profit Margin: BONEHU0223 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BONEHU0223 is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Accelerating Growth: Unable to compare BONEHU0223's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BONEHU0223 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: BONEHU0223 has a negative Return on Equity (-70.54%), as it is currently unprofitable.